';
zoom
KENGREXAL®
CANGRELOR (powder for solution to be diluted for injection/perfusion)
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease having undergone a percutaneous coronary intervention (PCI), who have not received an oral P2Y12 receptor inhibitor prior to the intervention and in whom the oral route for such a treatment is not feasible or desirable.
Useful links
European Commission
ec.europa.eu
French Healthcare Authority
has-sante.fr